Bio2 Technologies received FDA 510(k) clearance to market a fusion system for interphalangeal fusion, fracture repair and osteotomies of toes, fingers and other small bones in the presence of appropriate immobilization. The implants are made from Vitrium biomaterial, composed of resorbable bioactive glass. Limited product launch is slated for 2Q16.
We first noticed Bio2 in 2010, following its first round of funding. The company announced FDA 510(k) clearance for its CLM (Cross-Linked Microstructure) Bioactive Scaffold at the end of 2014. The CLM process bonds bioactive glass fiber into a rigid, 3-dimensional structure.
Bio2 Technologies received FDA 510(k) clearance to market a fusion system for interphalangeal fusion, fracture repair and osteotomies of toes, fingers and other small bones in the presence of appropriate immobilization. The implants are made from Vitrium biomaterial, composed of resorbable bioactive glass. Limited product launch is slated for...
Bio2 Technologies received FDA 510(k) clearance to market a fusion system for interphalangeal fusion, fracture repair and osteotomies of toes, fingers and other small bones in the presence of appropriate immobilization. The implants are made from Vitrium biomaterial, composed of resorbable bioactive glass. Limited product launch is slated for 2Q16.
We first noticed Bio2 in 2010, following its first round of funding. The company announced FDA 510(k) clearance for its CLM (Cross-Linked Microstructure) Bioactive Scaffold at the end of 2014. The CLM process bonds bioactive glass fiber into a rigid, 3-dimensional structure.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
Copy to clipboard 
